

Datasheet for 610-145-121**Mouse IgG (H&L) Antibody DyLight™ 800 Conjugated Pre-Adsorbed****Overview**

Description:	Goat Anti-Mouse IgG (H&L) Antibody DyLight™ 800 Conjugated (Min X Bv Ch Gt GP Ham Hs Hu Rb Rt & Sh Serum Proteins) - 610-145-121
Item No.:	610-145-121
Size:	100 µg
Applications:	Dot Blot, WB, IF
Reactivity:	Mouse
Host Species:	Goat

Product Details

Background:	Anti-Mouse IgG DyLight 800 Antibody generated in goat detects reactivity to Mouse IgG. Secreted as part of the adaptive immune response by plasma B cells, immunoglobulin G constitutes 75% of serum immunoglobulins. Immunoglobulin G binds to viruses, bacteria, as well as fungi and facilitates their destruction or neutralization via agglutination (and thereby immobilizing them), activation of the complement cascade, and opsonization for phagocytosis. The whole IgG molecule possesses both the F(c) region, recognized by high-affinity Fc receptor proteins, as well as the F(ab) region possessing the epitope-recognition site. Both the Heavy and Light chains of the antibody molecule are present. Secondary Antibodies are available in a variety of formats and conjugate types. When choosing a secondary antibody product, consideration must be given to species and immunoglobulin specificity, conjugate type, fragment and chain specificity, level of cross-reactivity, and host-species source and fragment composition.
Synonyms:	Goat Anti-Mouse IgG Secondary Antibody DyLight™800 Conjugated, Goat Anti-Mouse IgG Antibody DyLight™800 Conjugated, Anti-mouse IgG secondary antibody, anti-mouse IgG DyLight™800 conjugated secondary antibody
Host Species:	Goat
Specificity:	IgG (H&L)
Conjugate:	DyLight™ 800
Clonality:	Polyclonal
Format:	IgG
F/P Ratio:	2.25

Target Details

Reactivity:	Mouse
Immunogen:	Mouse IgG whole molecule
Purity/Specificity:	This product was prepared from monospecific antiserum by immunoaffinity chromatography using Mouse IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Goat Serum, Mouse IgG and Mouse Serum. No reaction was observed against Bovine, Chicken, Goat, Guinea Pig, Hamster, Horse, Human, Rabbit, Rat and Sheep Serum Proteins. This antibody will react with heavy chains of mouse IgG and with light chains of most mouse immunoglobulins.
Relevant Links:	• 610-145-121 SDS

Application Details

Tested Applications:	Dot Blot, WB
Suggested Applications:	IF (Based on references)
Application Note:	Anti-Mouse IgG DyLight 800 Antibody has been tested by dot blot and western blot and is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms. The emission spectra for this DyLight™ conjugate match the principle output wavelengths of most common fluorescence instrumentation.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
FLISA:	>1:20,000
IF:	>1:5,000
WB:	>1:10,000

Formulation

Physical State:	Lyophilized
Concentration:	1.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide

Stabilizer:	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Reconstitution Volume:	100 μ L
Reconstitution Buffer:	Restore with deionized water (or equivalent)

Shipping & Handling

Shipping Condition:	Ambient
Storage Condition:	Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.


Images

100ng 33.3ng 11.1ng 3.70ng 1.23ng



Dot Blot

Dot Blot results of Goat Anti-Mouse IgG Antibody DyLight™800 Conjugate. Dots are Mouse IgG: (1) 100ng, (2) 33.3ng, (3) 11.1ng, (4) 3.70ng, (5) 1.23ng. Primary Antibody: none. Secondary Antibody: Goat Anti-Mouse IgG Antibody DyLight™800 Conjugate at 1 μ g/mL in MB-070 1hr RT. Imaged with GBox, DyLight™ 800 Filter.


**Western Blot**

DyLight™ dyes can be used for two-color Western Blot detection with low background and high signal. Anti-tubulin was detected using a DyLight™ 680 conjugate. Anti-TNFα was detected using a DyLight™ 800 conjugate. The image was captured using the Odyssey® Infrared Imaging System developed by LI-COR.


Diagram

Properties of DyLight™ Conjugates.

Emission	Color	DyLight™ Dye	Ex/Em (nm)	ϵ ($M^{-1} cm^{-1}$)	Similar Dyes
Blue		405	400/420	30,000	Alexa™ 405, Cascade Blue
Green		488	493/518	70,000	Alexa™ 488, Cy2®, FITC
Yellow		549	550/568	150,000	Alexa™ 546, Alexa 555, Cy3®, TRITC
Red		649	646/674	250,000	Alexa™ 647, Cy5®
Near Infrared		680	682/715	140,000	Alexa™ 680, Cy5.5®, IRDye™ 700
Infrared		800	770/794	270,000	IRDye™ 800

**Western Blot**

Western Blot of Goat anti-Mouse IgG Antibody DyLight 800 Conjugated Pre-absorbed. Lane 1: Mouse IgG. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Goat anti-Mouse IgG Antibody DyLight 800 Conjugated Pre-absorbed at 1:1,000 for 60 min at RT. Block: MB-070 for 30 min at RT. Predicted/Observed size: 55 kDa, 25 kDa for Mouse IgG.



Diagram

References

- García-Poyatos C et al. Cox7a1 controls skeletal muscle physiology and heart regeneration through complex IV dimerization. *Dev Cell*. (2024)
- Cantacorps L et al. Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice. *Mol Metab*. (2024)
- Zhou Y et al. Targeting of HBP1/TIMP3 axis as a novel strategy against breast cancer. *Pharmacol Res*. (2023)
- Yang R et al. The transcription factor HBP1 promotes ferroptosis in tumor cells by regulating the UHRF1-CDO1 axis. *PLoS Biol*. (2023)
- Tapia-Galisteo A et al. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. *Oncoimmunology*. (2022)
- Zhang H et al. Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy. *Front Pharmacol*. (2022)
- Cao Z et al. HBP1-mediated transcriptional repression of AFP inhibits hepatoma progression. *J Exp Clin Cancer Res*. (2021)
- Liu Y et al. GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells. *Oncogenesis*. (2021)
- Xu S et al. IL-6 promotes nuclear translocation of HIF-1 α to aggravate chemoresistance of ovarian cancer cells. *Eur J Pharmacol*. (2021)
- Acin-Perez R et al. Analyzing electron transport chain supercomplexes. *Methods Cell Biol*. (2020)
- Garcia-Poyatos C et al. Scaf1 promotes respiratory supercomplexes and metabolic efficiency in zebrafish. *EMBO Rep*. (2020)
- Hosawi SB et al. Global proteomic analysis of insulin receptor interactors in glomerular podocytes. *Wellcome Open Res*. (2020)

- Woods BL. et al. Interplay of septin amphipathic helices in sensing membrane-curvature and filament bundling. *bioRxiv* (2020)
- Navarro R et al. TGF- β -induced IGFBP-3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion. *Mol Oncol.* (2020)
- Kennedy T et al. Genetic background mutations drive neural circuit hyperconnectivity in a fragile X syndrome model. *BMC Biol.* (2020)
- Owusu-Brckett N, Zhao M, Akcakanat A, et al. Targeting PI3K β alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. *Oncotarget.* (2020)
- Asthana V et al. Development of a Novel Class of Self-Assembling dsRNA Cancer Therapeutics: a Proof of Concept Investigation. *Mol Ther Oncolytics.* (2020)
- Mitra S, Bodor DL, David AF, et al. Genetic screening identifies a SUMO protease dynamically maintaining centromeric chromatin. *Nat Commun.* (2020)
- Takahashi H, Ranjan A, Chen S, et al. The role of Mediator and Little Elongation Complex in transcription termination. *Nat Commun.* (2020)
- Xue J et al. Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression. *Cancer Lett.* (2020)
- Zhao et al. FGFR1 β is a driver isoform of FGFR1 alternative splicing in breast cancer cells. *Oncotarget* (2019)
- Cao et al. MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1. *Oncogene* (2019)
- Guan J et al. Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. *Cell.* (2019)
- Weber MA et al. Enhanced dopamine D2 autoreceptor function in the adult prefrontal cortex contributes to dopamine hypoactivity following adolescent social stress. *Eur J Neurosci.* (2018)
- Compte et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. *Nature Communications* (2018)
- Lin et al. Emodin promotes the arrest of human lymphoma Raji cell proliferation through the UHRF1-DNMT3A- Δ Np73 pathways. *Molecular Medicine Reports* (2017)
- Binek et al. Proteomic footprint of myocardial ischemia/reperfusion injury: Longitudinal study of the at-risk and remote regions in the pig model. *Scientific Reports* (2017)
- Comps-Agrar L et al. The oligomeric state sets GABAB receptor signalling efficacy. *EMBO J.* (2011)
- Chacko AD et al. Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. *BMC Cancer.* (2010)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.